We next tested the Artelo Biosciences drug ART27.13, a synthetic peripherally selective cannabinoid receptor agonist, which has previously been shown to have an affinity for both CB1R and CB2R, albeit at a higher affinity for CB2R. Our studies into the efficacy of ART27.13 [100 nM] in combination with 30% CM illustrates that ART27.13 [100 nM] provides significant (at day 18 ART27.13 treatment versus vehicle, in 30% SW480 CM model, ** = p ≤ 0.01 and in 30% H1299 CM, *** = p ≤ 0.001) protection against the deleterious effects of both cancer CMs (Figure 6a,b). The gene discussed is CNR1; the disease is cancer.